Clinical trials: Active Non-segmental Vitiligo
Vitiligo
Oral Mini Pulse Dexamethasone in Pediatric Vitiligo
The goal of this clinical trial is to learn if oral mini pulse (OMP) dexamethasone works to treat active vitiligo in children and also learn about the safety of this drug within this age group the main questions it aims to answer…
- Trial name
- NCT07353801
- Testing
- Dexamethasone (0.1 mg/kg)
- Where
- Egypt
- Volunteers
- 22 people
- Sponsor
- Cairo University
Non-Segmental Vitiligo
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- NCT04927975
- Testing
- Upadacitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Vitiligo, Secukinumab
Secukinumab in Active Non-segmental Vitiligo
Vitiligo is an acquired autoimmune skin disorder which leads to cutaneous depigmentations. A lot of progress has been made to unravel the pathophysiology of vitiligo.
- Trial name
- NCT05676333
- Testing
- Secukinumab
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- University Hospital, Ghent
Active Non Segmental Vitiligo
Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.
This study aims at evaluating the effect of NB-UVB on tissue level of IL-15 and IL-15 receptor alpha subunit (IL-15Rα)(CD215) in active non segmental vitiligo.
- Trial name
- NCT05316987
- Testing
- Narrow band ultraviolet B
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
- Trial name
- Tranquillo (NCT05583526)
- Testing
- Ritlecitinib
- Where
- 115 sites in United States, Australia and 13 more
- Volunteers
- 607 people
- Sponsor
- Pfizer
Non-segmental Vitiligo
The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo
The aim of this study is to evaluate the influence of simvastatin and atorvastatin on vitiligous lesions in patients with non-segmental vitiligo.
- Trial name
- EVRAAS (NCT03247400)
- Testing
- 1% simvastatin-acid sodium salt ointment, 1% atorvastatin calcium salt ointment
- Where
- Poland
- Volunteers
- 24 people
- Sponsor
- Nicolaus Copernicus University
Patients With Active Non-segmental Vitiligo., Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%
Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo
Rationale: Vitiligo vulgaris is a common acquired pigment disorder, which is characterised by the development of depigmented macules. It develops probably due to immunedestruction of melanocytes.
- Conditions
- Patients With Active Non-segmental Vitiligo., Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%, Cream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo
- Trial name
- NCT01246921
- Testing
- Fluticasone proprionate 0.05% cream
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Active Non-segmental Vitiligo
A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks.
- Trial name
- NCT03715829
- Testing
- PF-06651600, PF06700841, narrow-band UVB phototherapy
- Where
- 92 sites in United States, Australia and 8 more
- Volunteers
- 366 people
- Sponsor
- Pfizer
Healthy, Active Non-segmental Vitiligo
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and…
- Conditions
- Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata
- Trial name
- NCT07554222
- Testing
- Baricitinib tablets, IBI3013
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-Segmental Vitiligo (NSV)
Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
This study is a prospective, multicenter, real-world observational study to assess the clinical efficacy and safety of topical 1.5% Ruxolitinib phosphate cream used in combination with systemic corticosteroids in a real-world…
- Trial name
- NCT07673640
- Testing
- 1.5% Ruxolitinib Phosphate Cream (Opzelura), Corticosteroid Therapy
- Where
- 20 sites in China
- Volunteers
- 300 people
- Sponsor
- ShanShan Li
Non-segmental Vitiligo
The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo
The aim of this study is to evaluate the influence of two concentrations of methotrexate on vitiligous lesions in patients with non-segmental vitiligo
- Trial name
- EVRAM (NCT04942860)
- Testing
- 1% Methotrexate gel, 0.5% Methotrexate gel
- Where
- Poland
- Volunteers
- 25 people
- Sponsor
- Nicolaus Copernicus University